Clinical Trial Update: A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating AK104/Tislelizumab plus chemotherapy as first-line treatment in PD-L1 TPS < 1% non-small cell lung cancer, currently not yet recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AK104/Tislelizumab (tislelizumab)
• Chemotherapy (chemotherapy)

Snippet

Sponsor: Akeso | Conditions: Locally Advanced or Metastatic NSCLC | Phase 3 | Status: NOT_YET_RECRUITING